Lung Cancer - Small Cell

Immunotherapy Breakthrough For Lung Cancer, The Biggest Cancer Killer | NBC Nightly News
Immunotherapy Breakthrough For Lung Cancer, The Biggest Cancer Killer | NBC Nightly News administrator 2 Views • 6 days ago

Doctors found that pre-treating lung cancer patients with immunotherapy drugs before they have surgery can help melt away the tumor and, at the same time, limit -- or even stop -- its spread.
» Subscribe to NBC News:
http://nbcnews.to/SubscribeToNBC
» Watch more NBC video: http://bit.ly/MoreNBCNews

NBC News is a leading source of global news and information. Here you will find clips from NBC Nightly News, Meet The Press, and original digital videos. Subscribe to our channel for news stories, technology, politics, health, entertainment, science, business, and exclusive NBC investigations.

Connect with NBC News Online!
Visit NBCNews.Com: http://nbcnews.to/ReadNBC
Find NBC News on Facebook: http://nbcnews.to/LikeNBC
Follow NBC News on Twitter: http://nbcnews.to/FollowNBC
Follow NBC News on Google+: http://nbcnews.to/PlusNBC
Follow NBC News on Instagram: http://nbcnews.to/InstaNBC
Follow NBC News on Pinterest: http://nbcnews.to/PinNBC

Immunotherapy Breakthrough For Lung Cancer, The Biggest Cancer Killer | NBC Nightly News

Patient preferences for non-small-cell lung cancer treatment: A qualitative study - Rosanne Janssens
Patient preferences for non-small-cell lung cancer treatment: A qualitative study - Rosanne Janssens administrator 1 Views • 2 years ago

In this presentation, Rosanne Janssens (KU Leuven) shares the findings from the qualitative study that was part of the PREFER case study on lung cancer. The recording was made 13 January 2022, and the presentation was part of the PREFER webinar on patient preferences for non-small-cell lung cancer treatment options.

Watch the full webinar:
https://youtu.be/1T9bpr3B06A
For more information about the project visit https://www.imi-prefer.eu/

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

This video and its contents reflect the PREFER project's view and not the view of IMI, the European Union or EFPIA.

Showing 1 out of 2